Indian-Made vs Imported Immunotherapy: What Actually Differs

No, not in the standard each product must meet. Every immunotherapy sold in India needs CDSCO marketing authorisation and Good Manufacturing Practice manufacture, whether it is imported or made here. An Indian biosimilar must be shown comparable to the reference product before approval. What genuinely differs is track record, price and supply-chain risk.

The question is almost always framed as two tiers — the “original imported one” and the “Indian one” — and that framing is wrong before the comparison starts. Three different things can appear on an Indian day-care chart, not two. Only one of them is a biosimilar.

Two of those three columns are not biosimilars at all. Keytruda and Opdyta are originator products. As of August 2026 the only Indian biosimilar of an immune checkpoint inhibitor marketed in India is Tishtha, the Zydus Lifesciences version of nivolumab, which reached patients on 22 January 2026. Pembrolizumab, atezolizumab, durvalumab and ipilimumab had no marketed Indian biosimilar at the time this page was reviewed.

For most patients offered immunotherapy in India today, the choice being worried about does not exist. There is one authorised product for the molecule prescribed, and for four of the five commonly used checkpoint inhibitors that product is an imported or imported-and-marketed originator. The decision has already been made by what is approved, not by anyone’s preference.

Where a choice does exist, the carton is a poor guide to it. Packaging reliably tells you the marketing company and the batch number. It does not reliably tell you which country the drug substance was manufactured in, and a familiar international brand name is not a promise of a European or American production line. What is verifiable is the CDSCO authorisation behind the product and the batch record your hospital pharmacy holds against it.

Through CDSCO, on one of two routes. A new molecule goes through the New Drugs and Clinical Trials Rules, 2019. An Indian biosimilar goes through the Guidelines on Similar Biologics, issued by CDSCO with the Department of Biotechnology in 2012 and revised in 2016. Neither route is a formality, and approval is granted indication by indication.

The two routes ask different questions. Set side by side, the difference is not strictness — it is what each applicant has to prove.

The word doing the work on the right-hand column is comparability. A biosimilar application is not asked to establish all over again that the molecule works; the reference product did that. It is asked to show that its version is not clinically meaningfully different from that reference product. That is a narrower question, which is why the programme is shorter and cheaper. It is also why the approval stays tied to the reference product’s indications instead of being granted freely.

One correction worth making early. An approval granted by the United States FDA or the European Medicines Agency does not by itself make a medicine legal to sell in India, and an Indian approval does not depend on either of them. Each regulator decides for its own market. This cuts both ways: a medicine used widely abroad may have no Indian approval, and an Indian authorisation is a real authorisation rather than a countersignature on someone else’s.

It shows comparability, not a head-to-head outcome trial. India’s only marketed checkpoint inhibitor biosimilar was approved on similarity data against its reference product, as the pathway requires. Long-term outcome comparisons between an Indian biosimilar and an imported originator in immunotherapy do not exist yet. Anyone claiming otherwise is overstating the evidence.

That is not a criticism of either product; it is what the regulatory design produces. Sorting what genuinely differs from what does not is the part that helps a family decide what to ask.

There is a much longer Indian record for biosimilars outside immunotherapy. Rituximab has had approved Indian biosimilars since 2007, trastuzumab since 2014, and bevacizumab in the years after that. All three are now routine in Indian cancer care. That history supports confidence in the pathway. It is not evidence about one specific 2026 checkpoint inhibitor product, and presenting it as though it were would be the same overreach in the opposite direction.

Where evidence is genuinely immature, saying so plainly is the honest position. No one yet holds years of Indian outcome data comparing a checkpoint inhibitor biosimilar with its reference product, because the product has been in patients for months. Post-marketing surveillance is how that gap is filled over time, which is exactly why a Phase IV condition sits on an approval like this one.

Clinical facts on this page follow published Indian regulatory guidance (CDSCO and the Department of Biotechnology) and general patient-education material from NCCN, ASCO and ESMO. No response rate, survival figure or outcome comparison is attributed to any named product on this page, because no such comparison exists for the Indian products discussed.

Immune checkpoint inhibitors, in any brand from any country, are not suitable for most people with cancer in India. They are approved for specific cancers at specific stages and treatment lines, and a great many patients have no eligible indication at all. Biomarker results, performance status, an active autoimmune condition needing immunosuppression, and a previous organ transplant are among the things that can rule this class of medicine out entirely. Whether immunotherapy is an option for you at all is settled long before any question of brand arises.

This page is also not a comparison of quality between named manufacturers, and it does not say that any one product is better than another. It makes no recommendation about which brand should be used for any patient. That decision belongs to the treating oncologist, who is choosing on the approved indication, the treatment plan and what the hospital can supply and account for — not on the country printed on the carton.

It is not a basis for asking to change molecules either. A biosimilar of nivolumab is not an alternative to pembrolizumab; they are different medicines with different approved indications, and a cheaper medicine that is not approved for your diagnosis is not an option at any price. Asking whether an approved alternative brand exists for the molecule you have already been prescribed is a different and entirely reasonable question, and your treating team can answer it directly.

Because the development path is shorter, not because the standard is lower. A comparability programme costs a fraction of an original discovery and trial programme. Domestic manufacture removes import cost. A second supplier entering a market has to price below the first. Those three things together, not a compromise on quality, produce the gap.

The published figures give the scale. When Zydus Lifesciences launched Tishtha in January 2026 it announced ₹28,950 for the 100 mg vial and ₹13,950 for the 40 mg vial, describing that as roughly a quarter of the reference product’s price. Those are manufacturer list prices, dated January 2026 and indicative only as of August 2026. They are not a CION rate, not a quote, and not a course cost — the number of vials a course needs depends on the prescribed dose and the number of cycles planned.

The timing was litigated rather than simply reached. A Delhi High Court division bench set aside an injunction in January 2026, allowing the launch to proceed, and the Supreme Court of India declined to interfere in February 2026; the underlying Indian patent protection ran to May 2026. Pembrolizumab is on a different clock, with its Indian protection reported as beginning to lapse around 2028-29, so there is no domestic version of that molecule to compare against today. Pembrolizumab vs Nivolumab: What Is the Difference? covers why the two most commonly prescribed PD-1 medicines in India sit in such different positions.

A lower drug price also does not move the lines around it. Day-care admission, nursing and infusion time, premedication, pre-cycle blood tests, response-assessment imaging at partner centres and side-effect management are billed the same whichever brand is used. Ask for an itemised quote rather than one bundled figure, so the drug line is visible separately from everything attached to it.

Not privately, and not as a way around the Indian product. Named-patient import does exist for specific situations, but it is arranged through the treating hospital under licence, not carried in personally. A privately obtained vial has no verifiable batch record and no cold-chain history. Counterfeit checkpoint inhibitors have been reported in India.

This is the question that comes up most often when a relative abroad is funding the treatment, and the instinct behind it is sound. You want to be certain the money buys the genuine article. The difficulty is that a personally imported vial removes the very controls that would let anyone confirm it.

An immunotherapy vial has to stay refrigerated within a narrow range from the manufacturing site to the infusion chair. A break in that chain is not visible in the vial. It is detectable only in the documentation, which is why hospital pharmacies keep it. A product bought outside that system — through an intermediary, online, or brought in by a traveller — arrives with no such record, whatever country it came from and however genuine the offer looked.

Counterfeit checkpoint inhibitors have been reported entering the Indian market around patent and pricing changes, and a wide price gap is exactly the environment in which a fake vial finds a buyer. Two rules follow, and neither should be softened. These medicines should be dispensed and administered through the treating hospital’s own licensed pharmacy. And it is entirely reasonable to ask to see the vial, the batch number, the invoice and the cold-chain record before an infusion — that is routine verification, not an accusation. How to check an immunotherapy vial is genuine sets out what to look at, and Counterfeit immunotherapy drugs in India explains what has actually been reported.

Six questions cover it. Which molecule is prescribed, and under which brand. Whether an approved alternative brand of that same molecule exists in India. Whether your indication sits on that brand’s Indian label. Where the medicine will be dispensed from. What the itemised cost is. And whether any brand change is planned mid-course.

1. Which molecule, and which brand? The molecule is the longer word ending in -mab. It decides the clinical picture. The brand tells you whose version is being used, and nothing more.
2. Is there an approved alternative brand of this same molecule in India? For four of the five commonly used checkpoint inhibitors the answer today is no, which settles the question quickly.
3. Is my indication on that brand’s Indian label? This is the question that matters more than country of origin, because an Indian approval is granted indication by indication.
4. Where will the medicine be dispensed from? The answer you want is the treating hospital’s own licensed pharmacy, with a batch record and a cold-chain record held against your infusion.
5. What is the itemised cost, drug line separated? The brand only moves the drug line. Seeing the rest listed separately makes the comparison an honest one.
6. Is a brand change planned part-way through the course? If one is proposed, ask for the reason and for it to be recorded on the chart, as any brand change should be.

None of these questions requires a confrontation, and none of them is unusual. A treating team that is choosing on indication, supply and accountability will have all six answers already.

The head-to-head pages below deal with choices between different molecules, which is a separate question from the brand-and-origin one this page answers.

• Pembrolizumab vs Nivolumab: What Is the Difference? — the two PD-1 medicines most often named on Indian prescriptions, and why only one of them has a domestic version.
• Atezolizumab vs Durvalumab in Small Cell Lung Cancer — two PD-L1 medicines compared in one specific disease setting, neither with an Indian biosimilar.
• Cemiplimab vs Pembrolizumab for Skin Cancer — a comparison where Indian availability itself is part of the answer.
• Immunotherapy Medicines Explained — the index of checkpoint inhibitors, biosimilars and molecule comparisons.
• Immunotherapy at a glance — what this class of treatment does, who it is for, and who it is not for.

Editorial information about a class of medicines and the routes by which they reach Indian patients — not an offer, a price list, a quality ranking between named manufacturers, or a recommendation to use any named product. All regulatory, patent and pricing statements are indicative and dated to August 2026, drawn from published regulatory guidance, court reporting and manufacturer announcements. Whether any of these medicines applies to your treatment, and in which brand, is a decision for your treating oncologist.